Elanco Animal Health patented an eye-drop composition for diagnosing and treating herpetic eye infections in companion animals. The composition includes 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one and a cyclodextrin. GlobalData’s report on Elanco Animal Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Elanco Animal Health Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Elanco Animal Health, NSAID cancer drugs was a key innovation area identified from patents. Elanco Animal Health's grant share as of February 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11904024B2) discloses a composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one and a cyclodextrin, with the former present at a concentration of at least 0.1% w/v and the latter at least 10% w/v. The composition is specified to be an aqueous solution, particularly designed as an ophthalmic solution. Additionally, the inclusion of hydroxypropyl beta-cyclodextrin and thiomersal at a concentration of at least 0.008% w/v is highlighted in the claims.

Moreover, the patent claims cover the use of this composition as a diagnostic or therapeutic agent, specifically for treating ocular herpetic infections in companion animals, particularly felines. The method involves applying the composition onto the eye two or three times per day for a minimum of seven days. Furthermore, the patent details a method for preparing the ophthalmic solution, involving the solubilization of 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one in a cyclodextrin solution, with the optional addition of thiomersal. The cyclodextrin specified in the method is hydroxypropyl beta-cyclodextrin, ensuring the stability and efficacy of the final ophthalmic solution.

To know more about GlobalData’s detailed insights on Elanco Animal Health, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies